223 related articles for article (PubMed ID: 34884975)
1. (20S) Ginsenoside Rh2 Exerts Its Anti-Tumor Effect by Disrupting the HSP90A-Cdc37 System in Human Liver Cancer Cells.
Chen C; Wang YS; Zhang ET; Li GA; Liu WY; Li Y; Jin YH
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884975
[TBL] [Abstract][Full Text] [Related]
2. (20S) Ginsenoside Rh2 Inhibits STAT3/VEGF Signaling by Targeting Annexin A2.
Wang YS; Chen C; Zhang SY; Li Y; Jin YH
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502195
[TBL] [Abstract][Full Text] [Related]
3. The identification of molecular target of (20S) ginsenoside Rh2 for its anti-cancer activity.
Wang YS; Lin Y; Li H; Li Y; Song Z; Jin YH
Sci Rep; 2017 Sep; 7(1):12408. PubMed ID: 28963461
[TBL] [Abstract][Full Text] [Related]
4. Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth.
Wang Z; Wei W; Sun CK; Chua MS; So S
Liver Int; 2015 Apr; 35(4):1403-15. PubMed ID: 25098386
[TBL] [Abstract][Full Text] [Related]
5. Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System.
Hallett ST; Pastok MW; Morgan RML; Wittner A; Blundell KLIM; Felletar I; Wedge SR; Prodromou C; Noble MEM; Pearl LH; Endicott JA
Cell Rep; 2017 Oct; 21(5):1386-1398. PubMed ID: 29091774
[TBL] [Abstract][Full Text] [Related]
6. Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway.
Qiang SQ; Qin GC; Jing L; Qiang FZ; Mei QH; Long CD
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2529-2539. PubMed ID: 34452568
[TBL] [Abstract][Full Text] [Related]
7. Cdc37 facilitates cell survival of colorectal carcinoma via activating the CDK4 signaling pathway.
Zhu J; Yan F; Tao J; Zhu X; Liu J; Deng S; Zhang X
Cancer Sci; 2018 Mar; 109(3):656-665. PubMed ID: 29288563
[TBL] [Abstract][Full Text] [Related]
8. Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.
Smith JR; de Billy E; Hobbs S; Powers M; Prodromou C; Pearl L; Clarke PA; Workman P
Oncogene; 2015 Jan; 34(1):15-26. PubMed ID: 24292678
[TBL] [Abstract][Full Text] [Related]
9. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors.
Smith JR; Clarke PA; de Billy E; Workman P
Oncogene; 2009 Jan; 28(2):157-69. PubMed ID: 18931700
[TBL] [Abstract][Full Text] [Related]
10. Antitumoral Activity of (20R)- and (20S)-Ginsenoside Rh2 on Transplanted Hepatocellular Carcinoma in Mice.
Lv Q; Rong N; Liu LJ; Xu XL; Liu JT; Jin FX; Wang CM
Planta Med; 2016 May; 82(8):705-11. PubMed ID: 27163230
[TBL] [Abstract][Full Text] [Related]
11. 20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription.
Li Q; Li B; Dong C; Wang Y; Li Q
Eur J Pharmacol; 2017 Nov; 815():173-180. PubMed ID: 28928088
[TBL] [Abstract][Full Text] [Related]
12. Ginsenoside Rh2 induces cell cycle arrest and differentiation in human leukemia cells by upregulating TGF-β expression.
Chung KS; Cho SH; Shin JS; Kim DH; Choi JH; Choi SY; Rhee YK; Hong HD; Lee KT
Carcinogenesis; 2013 Feb; 34(2):331-40. PubMed ID: 23125221
[TBL] [Abstract][Full Text] [Related]
13. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90.
Zhao M; Ma J; Zhu HY; Zhang XH; Du ZY; Xu YJ; Yu XD
Mol Cancer; 2011 Aug; 10():104. PubMed ID: 21871133
[TBL] [Abstract][Full Text] [Related]
14. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
Huang W; Ye M; Zhang LR; Wu QD; Zhang M; Xu JH; Zheng W
Mol Cancer; 2014 Jun; 13():150. PubMed ID: 24927996
[TBL] [Abstract][Full Text] [Related]
15. Cell Stress Induced Stressome Release Including Damaged Membrane Vesicles and Extracellular HSP90 by Prostate Cancer Cells.
Eguchi T; Sogawa C; Ono K; Matsumoto M; Tran MT; Okusha Y; Lang BJ; Okamoto K; Calderwood SK
Cells; 2020 Mar; 9(3):. PubMed ID: 32204513
[TBL] [Abstract][Full Text] [Related]
16. Anticancer effect of 20(S)-ginsenoside Rh2 on HepG2 liver carcinoma cells: Activating GSK-3β and degrading β-catenin.
Shi Q; Shi X; Zuo G; Xiong W; Li H; Guo P; Wang F; Chen Y; Li J; Chen DL
Oncol Rep; 2016 Oct; 36(4):2059-70. PubMed ID: 27573179
[TBL] [Abstract][Full Text] [Related]
17. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
18. Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases.
Choi S; Kim TW; Singh SV
Pharm Res; 2009 Oct; 26(10):2280-8. PubMed ID: 19629651
[TBL] [Abstract][Full Text] [Related]
19. Atomistic simulations and network-based modeling of the Hsp90-Cdc37 chaperone binding with Cdk4 client protein: A mechanism of chaperoning kinase clients by exploiting weak spots of intrinsically dynamic kinase domains.
Czemeres J; Buse K; Verkhivker GM
PLoS One; 2017; 12(12):e0190267. PubMed ID: 29267381
[TBL] [Abstract][Full Text] [Related]
20. Pseudo-ginsenoside Rh2 Induces Protective Autophagy in Hepatocellular Carcinoma HepG2 Cells.
Zhang F; Xu H; Xia R; Yu P; Li Y; Yu X; Sui D
Recent Pat Anticancer Drug Discov; 2021; 16(4):521-532. PubMed ID: 34109916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
